Rhythm Pharmaceuticals, Inc.


Company information coming soon

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transform the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases by rapidly advancing care and precision medicines addressing the root cause. Our science is dedicated to the understanding of hyperphagia and severe obesity caused by genetic variants leading to an impaired MC4R pathway. For more information about the science and our solutions, please visit our website http://www.path4hcps.com

Thank you for our sponsors who have supported the Association for the Study of Obesity (ASO) towards covering the costs of UKCO 2024. All sponsors have had no influence over the creation, development or content of the programme, apart from the Industry Led Symposium.

The UK Congress on Obesity has been instigated and organised by ASO. Sponsors have contributed funding towards this event in return for exhibition space. They have had no input into the agenda or the selection of speakers with the exception of any sponsored symposia which are clearly indicated. View a full list of sponsors.